Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

18 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Anthrax Vaccine Adsorbed Emergent BioSolutions Articles

Emergent BioSolutions gets $1.25 billion BioThrax order for US government

4 October 2011

PharmAthene gets additional $78.4 million under existing SparVax anthrax vaccine contract with HHS

24 February 2010

Emergent Bio's BioThrax OKed in India

16 February 2009

Shorter schedule approved for Emergent's BioThrax in USA

12 January 2009

Up to $448M US govt BioThrax contract

6 October 2008

Emergent gets HHS nod for Anthrax vacc contract

22 September 2008

Emergent Bio in anthrax vacc deal

12 May 2008

US government "wasting $100M" on anthrax drugs

29 October 2007

$448M HHS contract for Emergent Bio

8 October 2007

November a lackluster month for biotechnology stocks, says Burrill

18 December 2006

DOR plans deal with UK Ministry of Defence

20 January 2003

Showing 1-11 of 11 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS